Cargando…

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer

Mutations of the phosphoinositide-3-kinase (PI3K) catalytic subunit alpha gene (PIK3CA) are frequent in endometrial cancer. We sequenced exon9 and exon20 of PIK3CA in 280 primary endometrial cancers to assess the relationship with clinicopathologic variables, patient survival and associations with P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mjos, Siv, Werner, Henrica M. J., Birkeland, Even, Holst, Frederik, Berg, Anna, Halle, Mari K., Tangen, Ingvild L., Kusonmano, Kanthida, Mauland, Karen K., Oyan, Anne M., Kalland, Karl-Henning, Lewis, Aurélia E., Mills, Gordon B., Krakstad, Camilla, Trovik, Jone, Salvesen, Helga B., Hoivik, Erling A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578954/ https://www.ncbi.nlm.nih.gov/pubmed/28860563 http://dx.doi.org/10.1038/s41598-017-10717-z

Ejemplares similares

High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated
por: Krakstad, Camilla, et al.
Publicado: (2012)

Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer
por: Kusonmano, Kanthida, et al.
Publicado: (2018)

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients
por: Berg, Anna, et al.
Publicado: (2014)

ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma
por: Krakstad, Camilla, et al.
Publicado: (2015)

Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene
por: Hoivik, Erling A., et al.
Publicado: (2014)

Switch in FOXA1 Status Associates with Endometrial Cancer Progression
por: Tangen, Ingvild Løberg, et al.
Publicado: (2014)

Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival
por: Mauland, Karen Klepsland, et al.
Publicado: (2016)

Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients
por: Mauland, Karen Klepsland, et al.
Publicado: (2017)

High visceral fat percentage is associated with poor outcome in endometrial cancer
por: Mauland, Karen Klepsland, et al.
Publicado: (2017)

Androgen receptor as potential therapeutic target in metastatic endometrial cancer
por: Tangen, Ingvild Løberg, et al.
Publicado: (2016)

Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer
por: Werner, Henrica M. J., et al.
Publicado: (2014)

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012)

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors
por: Engerud, H, et al.
Publicado: (2014)

Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer
por: Berg, Anna, et al.
Publicado: (2016)

Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers
por: Berg, Anna, et al.
Publicado: (2017)

Blood Metabolites Associate with Prognosis in Endometrial Cancer
por: Strand, Elin, et al.
Publicado: (2019)

Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation
por: Karlsson, Thomas, et al.
Publicado: (2016)

Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value
por: Berg, Hege F., et al.
Publicado: (2022)

Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer
por: Stefansson, Ingunn M., et al.
Publicado: (2015)

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis
por: Gibson, William J., et al.
Publicado: (2016)

Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer
por: Mazloumi Gavgani, Fatemeh, et al.
Publicado: (2018)

PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis
por: Bredin, Hanna K., et al.
Publicado: (2023)

Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer
por: Engerud, Hilde, et al.
Publicado: (2019)

Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers
por: Raeder, Maria B., et al.
Publicado: (2013)

Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses
por: Bredholt, Geir, et al.
Publicado: (2015)

Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma
por: Berg, Hege F., et al.
Publicado: (2020)

Lipocalin 2 expression is associated with aggressive features of endometrial cancer
por: Mannelqvist, Monica, et al.
Publicado: (2012)

Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients
por: Tangen, Ingvild L, et al.
Publicado: (2017)

High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer
por: Mauland, K K, et al.
Publicado: (2011)

An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer
por: Jacob, Havjin, et al.
Publicado: (2021)

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome
por: Krakstad, C, et al.
Publicado: (2012)

Interobserver agreement and prognostic impact for MRI–based 2018 FIGO staging parameters in uterine cervical cancer
por: Wagner-Larsen, Kari S., et al.
Publicado: (2022)

What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer?
por: Lura, Njål, et al.
Publicado: (2022)

Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease
por: Lien, Hilde E., et al.
Publicado: (2023)

Corrigendum to “Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease” [EBioMedicine 92 (2023) 104595]
por: Lien, Hilde E., et al.
Publicado: (2023)

Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer
por: Fasmer, Kristine E., et al.
Publicado: (2020)

Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth
por: Holst, Frederik, et al.
Publicado: (2016)

Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth
por: Holst, Frederik, et al.
Publicado: (2016)

Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth
por: Holst, Frederik, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fo3ul5d47cqk4fgai087rgvi4v